8 completed, 8 recruiting, 4 terminated, 3 withdrawn. 24 Phase 1, 8 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 24 | Completed 8, Recruiting 8, Terminated 4, Withdrawn 3, Not yet recruiting 1 |
| Phase 2 | 8 | Recruiting 4, Terminated 2, Completed 1, Withdrawn 1 |
Follow Paraganglioma: new trials by email Literature Review of Paraganglioma trials Research Report on Paraganglioma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| 211At-MABG in Adults With Advanced Neuroendocrine Cancers 1 MBq/k of 211At-MABG Fractionated, 2 MBq/k1 of 211At-MABG Fractionated, 4 MBq/k of 211At-MABG Fractionated - Pheochromocytoma, Paraganglioma | Phase 1 | Not yet recruiting | University of Pennsylvania | 16 | 2026-12-01 | 2026-10-07 |
| Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors Biopsy, Biospecimen Collection, Computed Tomography - Metastatic Malignant Solid Neoplasm, Metastatic Melanoma | Phase 1 | Recruiting | Anusha Kalbasi | 18 | 2025-10-07 | 2026-03-17 |
| [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers [212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE - Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 120 | 2025-08-19 | 2026-10-06 |
| Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy 68Ga-DOTATATE, [203Pb]VMT-alpha-NET, [212Pb]VMT-alpha-NET - Somatostatin Receptor Positive, Gastrointestinal Neuroendocrine Tumors | Phase 1 / Phase 2 | Recruiting | National Cancer Institute (NCI) | 66 | 2025-02-07 | 2026-10-16 |
| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Olaparib; 177Lu-DOTATATE - Solid Tumor Cancer, Medulloblastoma | Phase 1 / Phase 2 | Recruiting | Fundación de investigación HM | 25 | 2024-09-20 | 2026-06-04 |
| A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors ADCT-701 - Neuroendocrine Carcinomas, Neuroendocrine Tumors | Phase 1 | Recruiting | National Cancer Institute (NCI) | 70 | 2024-06-17 | 2026-11-09 |
| Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors [203Pb]VMT-α-NET, [212Pb]VMT-α-NET - Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic | Phase 1 / Phase 2 | Recruiting | Perspective Therapeutics | 300 | 2023-09-27 | 2026-10-13 |
| HTL0039732 in Participants With Advanced Solid Tumours HTL0039732 Capsules, HTL0039732 Capsules or HTL0039732 tablets and atezolizumab infusion - Neoplasms, Prostatic Neoplasms, Castration-Resistant | Phase 1 / Phase 2 | Recruiting | Cancer Research UK | 150 | 2023-08-02 | 2026-10-01 |
| DFF332 as a Single Agent and in Combination With Everolimus & Immuno-Oncology Agents in Advanced/Relapsed Renal Cancer & Other Malignancies DFF332, RAD001, PDR001 - Carcinoma, Renal Cell | Phase 1 | Terminated | Novartis Pharmaceuticals | 40 | 2021-11-30 | 2026-03-03 |
| Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents 177Lu-DOTA-tyr3-OCTREOTATE, Peptide Receptor Radiotherapy (PRRT) - Neuroendocrine Tumors, Pheochromocytoma | Phase 1 / Phase 2 | Withdrawn | Sue O'Dorisio | 2020-08-04 | 2021-06-08 | |
| A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma EO2401, Nivolumab - Adrenocortical Carcinoma, Pheochromocytoma | Phase 1 / Phase 2 | Terminated | Enterome | 70 | 2020-07-23 | 2026-01-30 |
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Capecitabine, Temozolomide, Veliparib - Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma | Phase 1 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2017-12-01 | 2017-09-28 | |
| Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma Vandetanib, 131I-mIBG - Phaeochromocytoma, Paraganglioma | Phase 1 | Withdrawn | University College, London | 2014-10-01 | 2015-12-21 | |
| GA-68 DOTA-TOC of Somatostatin Positive Malignancies Computed Tomography (CT), Gallium Ga 68-Edotreotide, Magnetic Resonance Imaging (MRI) - Neuroendocrine Tumor, Paraganglioma | Phase 1 / Phase 2 | Terminated | University of California, San Francisco | 300 | 2014-06-23 | 2019-11-12 |
| Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma Cixutumumab, Everolimus, Laboratory Biomarker Analysis - Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor | Phase 1 | Completed | National Cancer Institute (NCI) | 27 | 2010-10-01 | 2016-07-15 |
| Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors temsirolimus, vinorelbine ditartrate - Extensive Stage Small Cell Lung Cancer, Hereditary Paraganglioma | Phase 1 | Completed | University of Southern California | 19 | 2010-06-01 | 2016-06-13 |
| Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors vorinostat, temozolomide, diagnostic laboratory biomarker analysis - Childhood Atypical Teratoid/Rhabdoid Tumor, Childhood Central Nervous System Choriocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 27 | 2010-02-01 | 2013-05-03 |
| Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma Ultratrace Iobenguane (MIBG) I 131 - Pheochromocytoma, Paraganglioma | Phase 1 / Phase 2 | Completed | Molecular Insight Pharmaceuticals, Inc. | 24 | 2007-04-01 | 2016-07-13 |
| ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid Ultratrace iobenguane I 131 - Pheochromocytoma, Paraganglioma | Phase 1 | Completed | Molecular Insight Pharmaceuticals, Inc. | 24 | 2006-06-01 | 2011-10-12 |
| Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors everolimus, vatalanib, pharmacological study - Gastrinoma, Glucagonoma | Phase 1 | Completed | Mayo Clinic | 96 | 2004-12-01 | 2024-08-21 |
Showing 20 of 24. Sign in to see all of them.
Pheochromocytoma (21) · Neuroendocrine Tumors (11) · Carcinoma, Medullary (6) · Insulinoma (6) · Carcinoma, Islet Cell (5) · Carcinoma, Merkel Cell (5) · Glucagonoma (5) · Neuroblastoma (5) · Somatostatinoma (5) · Carcinoma, Renal Cell (4) · Gastrinoma (4) · Adenoma, Islet Cell (3) · Adrenocortical Carcinoma (3) · Carcinoid Tumor (3)
Neoplasms by Histologic Type (24) · Neoplasms, Germ Cell and Embryonal (24) · Neoplasms, Nerve Tissue (24) · Neuroectodermal Tumors (24) · Neoplasms (21) · Neoplasms, Glandular and Epithelial (18) · Neoplasms by Site (16) · Carcinoma (15) · Adenocarcinoma (14) · Neuroendocrine Tumors (13) · Endocrine Gland Neoplasms (12) · Endocrine System Diseases (12) · Digestive System Diseases (9) · Digestive System Neoplasms (9) · Pancreatic Diseases (9)
Everolimus (3) · gallium Ga 68 dotatate (3) · 3-Iodobenzylguanidine (2) · Magnetic Resonance Spectroscopy (2) · Temozolomide (2) · lutetium Lu 177 dotatate (2) · 6-fluorodopamine (1) · Acetates (1) · Biopsy (1) · Capecitabine (1) · Cyclophosphamide (1) · Floxuridine (1) · Fluorodeoxyglucose F18 (1) · High-Energy Shock Waves (1) · Interleukin-13 (1)
National Cancer Institute (NCI) (5) · Molecular Insight Pharmaceuticals, Inc. (2) · Anusha Kalbasi (1) · Cancer Research UK (1) · Enterome (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · Fundación de investigación HM (1) · Mayo Clinic (1) · Memorial Sloan Kettering Cancer Center (1) · Novartis Pharmaceuticals (1) · O'Dorisio, M S (1) · Perspective Therapeutics (1) · Sue O'Dorisio (1) · University College, London (1) · University of California, San Francisco (1)
United States (19) · Spain (3) · France (2) · Italy (2) · United Kingdom (2) · Canada (1) · Czechia (1) · Denmark (1) · Germany (1) · Japan (1) · Netherlands (1) · Singapore (1) · Sweden (1)
Frank I Lin, M.D. (2) · M. Sue O'Dorisio, MD, PhD (2) · Agustin Garcia (1) · Allison Betof Warner, MD, PhD (1) · Antoni Ribas, MD, PhD (1) · Catherine M Gordon, M.D. (1) · Christina Thirlwell (1) · James Yao (1) · Jaydira Del Rivero, M.D. (1) · Jean-Michel Paillarse (1) · John R. Murren, MD (1) · Jordan Berlin, M.D. (1) · Julian R. Molina, M.D., Ph.D. (1) · Leonard B. Saltz, MD (1) · Marta Osuna Marco, PhD (1)
PMID 20847174, PMID 23554030, PMID 25900182, PMID 29099942, PMID 29534198, PMID 31057686, PMID 31231443, PMID 34431366, PMID 39416174, PMID 40595495, PMID 42558019
P30CA016672 (1), R01CA300202 (1), U01CA062461 (1), U01CA097452 (1)